Exosome analysis in patients with marked hypercholesterolemia or Lp(a) hypercholesterolemia receiving chronic lipoprotein apheresis or PCSK9 inhibitor therapy. - Ex(2)LAPH-Study

ephrologisches Zentrum Göttingen0 个研究点目标入组 50 人开始时间: 2023年7月4日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Familial hypercholesterolemia (HLP IIa) and a history of a cardiovascular event (CHD, PAVK, apoplexy, significant plaques).
•- therapy with a statin for 6 months in monotherapy or in combination with PCSK-9 inhibition and or apheresis therapy.
•- presence of a written informed consent

•Known intolerance or relevant adverse events to statins in the past history
•- new-onset intolerance to any of the therapies used
•- lack of capacity to give consent
•- withdrawal of consent
•- insufficient mental capacity (psychiatric treatment)
•- pregnancy
•- preterminal malignant disease
•- malignant hypertension
•- acute renal failure
•- untreated diabetes mellitus
•- untreated hyper- or hypothyroidism
•- clinically important hepatic, gastrointestinal, hematologic, pulmonary, or neurologic disorders
•- alcohol, drug or medication abuse
•- occurrence of serious complications (Serious Adverse Events)
•- low hemoglobin level (<10 g/dl)

发起方

ephrologisches Zentrum Göttingen